Treatment of spinocerebellar ataxia with mesenchymal stem cells: A phase I/IIa clinical study

Yun An Tsai, Ren Shyan Liu, Jiing Feng Lirng, Bang Hung Yang, Chin Hao Chang, Yi Chen Wang, Yu Shan Wu, Jennifer Hui Chun Ho, Oscar K. Lee, Bing Wen Soong

Research output: Contribution to journalArticlepeer-review

42 Citations (Scopus)


Ataxia is one of the most devastating symptoms of many neurodegenerative disorders. As of today, there is not any effective treatment to retard its progression. Mesenchymal stem cells (MSCs) have shown promise in treating neurodegenerative diseases. We hereby report the results of a phase I/IIa clinical study conducted in Taiwan to primarily evaluate the safety, tolerability, and, secondarily, the possible efficacy of intravenous administration of allogeneic adipose tissue-derived MSCs from healthy donors. Six patients with spinocerebellar ataxia type 3 and one with multiple system atrophy-cerebellar type were included in this open-label study with intravenous administration of 106 cells/kg body weight. The subjects were closely monitored for 1 year for safety (vital signs, complete blood counts, serum biochemical profiles, and urinalysis) and possible efficacy (scale for assessment and rating of ataxia and sensory organization testing scores, metabolite ratios on the brain magnetic resonance spectroscopy, and brain glucose metabolism of 18-fluorodeoxyglucose using positron emission tomography). No adverse events related to the injection of MSCs during the 1-year follow-up were observed. The intravenous administration of allogeneic MSCs seemed well tolerated. Upon study completion, all patients wished to continue treatment with the allogeneic MSCs. We conclude that allogeneic MSCs given by intravenous injection seems to be safe and tolerable in patients with spinocerebellar ataxia type 3, thus supporting advancement of the clinical development of allogeneic MSCs for the treatment of spinocerebellar ataxias (SCAs) in a randomized, double-blind, placebo-controlled phase II trials.

Original languageEnglish
Pages (from-to)503-512
Number of pages10
JournalCell Transplantation
Issue number3
Publication statusPublished - 2017


  • Allogeneic mesenchymal stem cells (MSCs)
  • Clinical trials
  • Gait disorders/ataxia
  • Spinocerebellar ataxias (SCAs)
  • Trinucleotide repeat diseases

ASJC Scopus subject areas

  • Biomedical Engineering
  • Cell Biology
  • Transplantation


Dive into the research topics of 'Treatment of spinocerebellar ataxia with mesenchymal stem cells: A phase I/IIa clinical study'. Together they form a unique fingerprint.

Cite this